<DOC>
	<DOCNO>NCT02421588</DOCNO>
	<brief_summary>Multicenter , open-label , randomize , control phase III clinical trial evaluate activity safety PM01183 versus PLD topotecan control arm patient platinum-resistant ovarian cancer . PM01183 explore single agent experimental arm ( Arm A ) versus PLD topotecan control arm ( Arm B ) .</brief_summary>
	<brief_title>Clinical Trial Lurbinectedin ( PM01183 ) Platinum Resistant Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Age &gt; /= 18 year Confirmed diagnosis unresectable epithelial ovarian , fallopian tube primary peritoneal cancer . Platinumresistant disease ( PFI : 16 month last platinumcontaining chemotherapy ) . Evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) v.1.1 criterion No three prior systemic chemotherapy regimens Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ( ECOG PS ) â‰¤ 2 Adequate hematological , renal , metabolic hepatic function Concomitant diseases/conditions : cardiac disease , immunodeficiency , chronic active hepatitis cirrhosis , uncontrolled infection , bowel obstruction , major illness Prior treatment PM01183 , trabectedin , PLD topotecan . Requirement permanent frequent ( i.e. , per week ) external drainage within two week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>